摘要
目的 研究异基因造血干细胞移植（allo-HSCT）预处理患者静脉输注大剂量白消安的药动学特征。方法 17例allo-HSCT预处理患者静脉输注白消安0.8 mg·kg-1，q6h，共16剂。在首剂和第9剂给药时，分别于给药前及给药后不同时间点采集血样，用高效液相色谱法测定血浆白消安浓度，用DAS软件进行药动学房室模型拟合，计算药动学参数。结果 首剂和第9剂静脉滴注给药后白消安在allo-HSCT预处理患者体内过程均符合二室模型，其主要药动学参数分别为：CL（0.004 2±0.001 8）与（0.002 8±0.001 3）L·min-1·kg-1、AUC0-t（612.3±182.8）与（1 005.4±286.2）μmol·min·L-1、AUC0-∞ （899.5±298.6）与（1 484.4±623.0）μmol·min·L-1；ρmax（2.95±0.81）与（4.53±1.42）μmol·L-1。不同性别患者的主要药动学参数有显著差异。结论 静脉滴注白消安在allo-HSCT预处理患者体内过程符合二室药动学模型，主要药动学参数个体差异大且与性别有关，开展治疗药物监测仍有必要。
Abstract
OBJECTIVE To study the pharmacokinetic profiles of intravenous busulfan in Chinese patients undergoing allogeneic hematopoietic stem cell transplantation. METHODS Blood samples of 17 adult patients were collected following the first and the ninth dose of a standard 16 dose intravenous busulfan，4-day regimen. The plasma concentrations of busulfan were determined by HPLC， and the pharmacokinetic parameters of busulfan were calculated by DAS statistical softwere. RESULTS The plasma concentration-time curves after dose 1 and dose 9 intravenous busulfan of 0.8 mg·kg-1 in 17 patients were fit to a two-compartment model，respectively. The main pharmacokinetic parameters were as follow：CL （0.004 2±0.001 8） and （0.002 8±0.001 3）L·min-1·kg-1， AUC0-t（612.3±182.8） and （1 005.4±286.2） μmol·min·L-1， AUC0-∞ （899.5±298.6） and （1 484.4±623.0） μmol·min·L-1， ρmax（2.95±0.81） and （4.53±1.42）μmol·L-1， respectively. The main pharmacokinetic parameters after intravenous administration of busulfan 0.8 mg·kg-1 were different between female and male. CONCLUSION The pharmacokinetic profiles of intravenous busulfan are fit to two-compartment model，the inter- and intrapatient variability in the main pharmacokinetic parameters（such as CL, AUC0-t, AUC0-∞ and ρmax are significant statistically and related to gender. Intravenous busulfan pharmacokinetics should need more research and the therapeutic monitoring and appropriate dose adjustment may be recommended.
关键词
白消安 /
异基因造血干细胞移植
{{custom_keyword}} /
张善堂 方焱 孙自敏 刘会兰 耿良权 唐丽琴 孙言才 吴云 谯川南 屈建.
静脉输注白消安在异基因造血干细胞移植预处理患者体内的药动学研究[J]. 中国药学杂志, 2010, 45(12): 935-939
ZHNG Shn-tng;FNG Yn;SUN Zi-min;LIU Hui-ln;GENG Ling-qun;TNG Li-qin;SUN Yn-ci;WU Yun;QIO Chun-nn;QU Jin.
Pharmacokinetics of Intravenous Busulfan in Patients Prior to Allogeneic Hematopoietic Stem Cell Transplantation[J]. Chinese Pharmaceutical Journal, 2010, 45(12): 935-939
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] ZHANG S T，SUN Z M. Therapeutic drug monitoring of busulfan and its application in hematopoietic stem cell transplantation[J]. Chin Hosp Pharm J（中国医院药学杂志），2009，29(3)：228-232.
[2] CIUREA S O，ANDERSSON B S. Busulfan in hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant，2009，15(5)：523-536.
[3] RUSSELL J A，KANGARLOO S B. Therapeutic drug monitoring of busulfan in transplantation[J]. Curr Pharm Des，2008，14(20)：1936-1949.
[4] ZHU K E，XU Y，ZHONG J，et al. BU-CTX_2 as conditioning regimen for allogeneic hematopoietic stem cell transplantation in sixty patients with leukemia[J]. Chin J Hematol（中华血液学杂志），2002，23(7)：349-352.
[5] TONG X Z， XU D R， ZOU W Y，et al. Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia[J]. Chin J Cancer（癌症）， 2007， 26(8)： 914- 918.
[6] ZHANG S T，SUN Z M，LIU H L，et al. Pharmacokinetics of oral busulfan in patients undergoing allogeneic hematopoietic stem cell transplantation[J]. Chin Pharm J（中国药学杂志），2009，44（18）：1416-1419.
[7] SUN Z M，WANG Z Y，LIU H L，et al. Allogeneic hematopoietic stem cell transplantation in the treatment of hematological malignancies[J]. J Clin Hematol(临床血液学杂志)，2004，17(5)：257-260.
[8] ZHANG S T，FENG Y，QU J，et al. Determination of busulfan in human plasma by HPLC with pre-colum derivatization[J].Chin Hosp Pharm J（中国医院药学杂志），2007，27（4）：458-461.
[9] HASSAN Z，LJUNGMAN P，RINGDN O，et al. Pharmacokinetics of liposomal busulphan in man[J].Bone Marrow Transplant，2001，27(5)：479-485.
[10] NATH C E，EARL J W，PATI N，et al. Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients[J]. Br J Clin Pharmacol，2008，66(1)：50-59.
[11] CHO Y H，LIM H A，LEE M H，et al. Pharmacokinetics and tolerability of intravenous busulfan in hematopoietic stem cell transplantation[J]. Clin Transplant，2007，21(3)：417-422.
[12] MADDEN T， DE LIMA M，THAPAR N，et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens：a comparison with an every 6-hour dosing schefule[J]. Biol Blood Marrow Transplant，2007，13(1)：56-64.
[13] FERNANDEZ H F，TRAN H T，ALBRECHT F，et al. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation[J]. Biol Blood Marrow Transplant，2002，8(9)：486-492.
[14] ANDERSSON B S， THALL P F， MADDEN T， et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease： defining a therapeutic window for IV BuCy2 in chronic myelogenous leukemia[J]. Biol Blood Marrow Transplantation， 2002，8(9)：477-485.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(1040 KB)
